Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04066361 · ClinicalTrials.gov registry record · NA

OPTimizing Treatment Focused Genetic Testing IN Cancer

A NA study of Breast Cancer and Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
301
Enrollment target
1
Study location

NCT04066361 is a NA study of Breast Cancer and Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 301 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04066361, a NA study of Breast Cancer and Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
301 participants
Enrollment target
1
Study location

Study Summary

This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.

Interventions

  • OTHER Chatbot
  • OTHER Video Education

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2019-12-19
Est. Completion 2022-11-30
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04066361

The ClinicalTrials.gov registry entry for NCT04066361 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chatbot is the first listed.

NCT04066361 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04066361 about?

NCT04066361 is a clinical study titled "OPTimizing Treatment Focused Genetic Testing IN Cancer". This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.

What is the current status of trial NCT04066361?

This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2019-12-19. Estimated completion is 2022-11-30.

What conditions does trial NCT04066361 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.

What interventions are being tested in trial NCT04066361?

The interventions under investigation include: Chatbot (OTHER), Video Education (OTHER).

Who is sponsoring clinical trial NCT04066361?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04066361 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.